This article was accepted into the corpus but its outbound wikilinks were never NER-processed — typical at the deepest BFS hop or when the run's entity cap was reached. No expansion funnel to show.
| MAPK (mitogen-activated protein kinase) | |
|---|---|
| Name | Mitogen-activated protein kinase |
MAPK (mitogen-activated protein kinase) is a family of serine/threonine protein kinases that transduce extracellular signals into intracellular responses. Discovered in studies linking Epidermal growth factor responses to transcriptional changes, MAPKs connect membrane receptors to nuclear effectors and integrate inputs from growth factors, stressors, and cytokines. MAPKs are central nodes in signaling networks studied across models including Saccharomyces cerevisiae, Drosophila melanogaster, Mus musculus, and human cell lines used in research at institutions such as the National Institutes of Health and Max Planck Society.
MAPKs were characterized through work involving Harvard University laboratories and collaborations with groups at Cold Spring Harbor Laboratory and Stanford University that linked receptor tyrosine kinases like Epidermal growth factor receptor and Platelet-derived growth factor receptor to downstream transcription factors such as c-Fos and Elk-1. Early biochemical descriptions referenced kinases from studies on Xenopus laevis oocytes and yeast pheromone responses in University of Cambridge research. The MAPK paradigm expanded via contributions from researchers associated with awards like the Nobel Prize in Physiology or Medicine and meetings hosted by societies including the American Society for Biochemistry and Molecular Biology.
MAPKs share a conserved kinase domain with motifs identified in structural studies at facilities like European Molecular Biology Laboratory and Brookhaven National Laboratory. Major mammalian subfamilies include extracellular signal-regulated kinases (ERK1/2) studied in University of California, San Francisco labs, c-Jun N-terminal kinases (JNK1/2/3) explored at Massachusetts Institute of Technology, and p38 MAPKs (p38α/β/γ/δ) characterized in work affiliated with Johns Hopkins University and University College London. Isoforms arise from genes mapped on chromosomes in consortia such as the Human Genome Project and annotated in databases curated by European Bioinformatics Institute and National Center for Biotechnology Information. High-resolution crystal structures from teams at Yale University and University of Oxford revealed activation loop and ATP-binding pocket conformations important for inhibitor design by pharmaceutical groups like Pfizer and Novartis.
Activation proceeds through three-tiered cascades involving MAP kinase kinases (MKKs/MAP2Ks) and MAP kinase kinase kinases (MAP3Ks) defined in pathway maps used by researchers at Wellcome Trust and Howard Hughes Medical Institute. Receptor classes including Toll-like receptor, G-protein-coupled receptor, Insulin receptor, and Transforming growth factor beta receptor engage adaptor proteins characterized by studies at Scripps Research and Karolinska Institutet, then recruit MAP3Ks such as RAF kinase family members described in clinical research at Memorial Sloan Kettering Cancer Center. Downstream targets include transcription factors investigated in laboratories at Columbia University and University of Toronto, and cell-cycle regulators examined in studies at Cold Spring Harbor Laboratory.
MAPK pathways regulate proliferation, differentiation, apoptosis, and stress responses observed in developmental biology work on Caenorhabditis elegans and neural development studies at University of Cambridge. In immunology contexts, MAPKs modulate cytokine production characterized in experiments at Pasteur Institute and vaccine studies at Bill & Melinda Gates Foundation–funded centers. In cardiovascular research at Mayo Clinic and Cleveland Clinic, MAPK signaling affects hypertrophy and ischemia–reperfusion responses. In oncology, aberrant MAPK activity underlies tumorigenesis investigated by groups at Dana-Farber Cancer Institute and clinical trials coordinated by European Society for Medical Oncology.
Regulation includes dual-specificity phosphatases (DUSPs) studied at Vanderbilt University and scaffold proteins such as KSR examined in work at University of Chicago. Negative feedback loops were delineated in systems biology efforts at Santa Fe Institute and computational modeling groups at Carnegie Mellon University and ETH Zurich. Cross-talk with pathways including PI3K–AKT pathway and NF-κB pathway has been reported in consortium projects led by National Cancer Institute and collaborative networks like Human Cell Atlas. Post-translational modifications and ubiquitin-mediated turnover involve enzymes characterized at Rockefeller University and Max Delbrück Center for Molecular Medicine.
Mutations and dysregulation of MAPK components are implicated in cancers such as melanoma where BRAF V600E mutations have driven therapies developed by companies including GlaxoSmithKline and Roche. Developmental disorders (RASopathies) with mutations in RAS–MAPK components are studied in clinics affiliated with Boston Children's Hospital and registries coordinated by European Reference Networks. Neurodegenerative conditions linked to JNK signaling have been investigated by teams at University College London and Salk Institute. Anti-cancer drugs targeting MAPK signaling, including MEK inhibitors and RAF inhibitors, have advanced through trials overseen by regulatory agencies like the Food and Drug Administration and European Medicines Agency.
Detection and analysis employ techniques established in core facilities at Broad Institute and European Synchrotron Radiation Facility, including immunoblotting with phospho-specific antibodies produced by suppliers such as Cell Signaling Technology and mass spectrometry performed in proteomics centers at Max Planck Institute for Biochemistry. Genetic manipulation methods using CRISPR workflows from Broad Institute and RNA interference approaches developed at Whitehead Institute enable functional studies. Live-cell imaging and biosensors for MAPK activity were advanced in labs at Howard Hughes Medical Institute and instrumentation by companies like Zeiss and Leica Microsystems support kinetics measurements.